Daniel Grau, Avilar CEO

An RA-backed start­up 'AT­AC­s' a nov­el chal­lenge, look­ing to spur pro­tein degra­da­tion out­side the cell

Pro­tein degra­da­tion is one of the hot drug class­es of the fu­ture, but com­peti­tors are pil­ing in with the likes of C4, Arv­inas, Fron­tier Med­i­cines and Vi­vid­ion jostling for po­si­tion. A new start­up wants to ap­ply the lessons learned from degra­da­tion out­side the cell, and it now has the green­light from RA Cap­i­tal to steam ahead.

Avi­lar Ther­a­peu­tics launched Thurs­day with $60 mil­lion from found­ing in­vestor RA to chase a nov­el pro­tein degra­da­tion drug class the start­up is call­ing AT­ACs— short for “AS­G­PR Tar­get­ing Chimeras” — that looks to trash un­want­ed pro­teins cir­cu­lat­ing out­side the hu­man cell.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.